OBJECTIVES: To describe adherence in Crohn’s disease (CD) patients receiving infliximab (IFX) by site-of-care (SOC). METHODS: The Humana claims database was utilized to identify patients aged 18-89 with CD newly initiating IFX treatment between 7/1/2007 and 7/31/2011.  Index date was the date of first IFX claim; 6 months pre- and 12 month post-index were required. Medication Possession Ratio (MPR) was calculated as [sum days’ supply of IFX based on infusion dates and assumed duration of action]/[sum days’ between first infusion and last days supply of last infusion]; therefore patients required ≥2 infusions.  SOC types included physician office, outpatient hospital department, and ambulatory infusion centers. SOC was classified as ≥75% of infusions from one site; patients without a majority of infusions from one site were classified as mixed-site. RESULTS: A total of 173 patients were identified; 156 had at least 2 infusions.  Mean age was 47.9 years, 59.5% were female, and 53.8% had Commercial coverage. Hospital outpatient (48.0%) and physician office (36.4%) were the most common SOC for index dose; among those who reached the maintenance phase, this same trend was observed. Mean MPR was similar across SOC (range 0.8 to 0.9, p-value 0.4412).  Further, the proportion of patients considered adherent (≥80% MPR) was 72.4% among patients with physician office as primary SOC.   The proportion of patients with ≥80% MPR in the other site types were similar to that of physician office patients (61.3%, 71.4%, and 81.0% for hospital outpatient, ambulatory infusion centers, and mixed site, respectively; p-value=NS). CONCLUSIONS: IFX adherence rates among CD patients did not vary significantly across different sites of care. Research evaluating other factors, such as patients’ preferences and satisfaction, may be useful in further characterizing available sites of care and supporting optimal site of care selection.